Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M.
Cancer. 2012 Jan 26. doi: 10.1002/cncr.27411. [Epub ahead of print]
Related citations
Lung cancer with translocation in the anaplastic lymphoma kinase gene: A disease within a disease.
Ramalingam SS, Khuri FR.
Cancer. 2012 Jan 26. doi: 10.1002/cncr.27402. [Epub ahead of print] No abstract available.
Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.
Sugawara E, Togashi Y, Kuroda N, Sakata S, Hatano S, Asaka R, Yuasa T, Yonese J, Kitagawa M, Mano H, Ishikawa Y, Takeuchi K.
Cancer. 2012 Jan 17. doi: 10.1002/cncr.27391. [Epub ahead of print]
Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: Involved-field versus involved-node radiotherapy.
Campbell BA, Connors JM, Gascoyne RD, Morris WJ, Pickles T, Sehn LH.
Cancer. 2012 Jan 17. doi: 10.1002/cncr.26687. [Epub ahead of print]
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A.
Cancer. 2012 Jan 17. doi: 10.1002/cncr.27418. [Epub ahead of print]
Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N, Uner A, Benekli M, Barista I.
Cancer. 2011 Dec 27. doi: 10.1002/cncr.27396. [Epub ahead of print]
Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, Hashimoto C, Tamura K, Sato K, Ishigatsubo Y.
Cancer. 2011 Dec 27. doi: 10.1002/cncr.27381. [Epub ahead of print]
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, Miller M, Toth P, Lizotte PM, Nasta S, Goldberg S, Chong E, Schuster S, Pecora AL, Goy A.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26731. [Epub ahead of print]
Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26723. [Epub ahead of print]
Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26709. [Epub ahead of print]
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: Phase 2 study of the Italian Lymphoma Foundation.
Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, Merli F, Rigacci L, Stelitano C, Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26708. [Epub ahead of print]
Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008.
Sharaiha RZ, Lebwohl B, Reimers L, Bhagat G, Green PH, Neugut AI.
Cancer. 2011 Dec 13. doi: 10.1002/cncr.26700. [Epub ahead of print]
Phase 2 trial of "Sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, Zhang W, Ji X, Li P, Chen N, Zhao S, Wang F, Zou L.
Cancer. 2011 Dec 2. doi: 10.1002/cncr.26629. [Epub ahead of print]
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
Lee JK, Park HS, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH, Heo DS, Kim WH, Bang YJ.
Cancer. 2011 Nov 15. doi: 10.1002/cncr.26668. [Epub ahead of print]
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database.
Kumar A, Vanderplas A, Lacasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA.
Cancer. 2012 Jun 1;118(11):2944-51. doi: 10.1002/cncr.26588. Epub 2011 Oct 17.
A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.
Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S.
Cancer. 2011 Oct 17. doi: 10.1002/cncr.26510. [Epub ahead of print]
Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ.
Cancer. 2012 Mar 15;118(6):1566-73. doi: 10.1002/cncr.26433. Epub 2011 Aug 31.
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, Schwager SM, Thompson CA, Bowen DA, Witzig TE, Slager SL, Call TG.
Cancer. 2012 Apr 1;118(7):1827-37. doi: 10.1002/cncr.26474. Epub 2011 Aug 26.
Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma.
Lu NN, Li YX, Wang WH, Jin J, Song YW, Zhou LQ, Wang SL, Liu YP, Liu XF, Yu ZH.
Cancer. 2012 Mar 15;118(6):1593-8. doi: 10.1002/cncr.26452. Epub 2011 Aug 11.
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.
Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.
Cancer. 2012 Feb 1;118(3):848-55. doi: 10.1002/cncr.26341. Epub 2011 Jul 12.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on